Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

In response to several high-profile drug misadventures including the rofecoxib (Vioxx®) withdrawal from the market, the FDA's Center for Drug Evaluation and Research (CDER) asked the Institute of Medicine (IOM) to assess the drug safety system in the United States.

Pharmacology Watch